The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control ... known for introducing cost-effective options, and the drug being indicated for ...

Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...

Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with ...